Jonathan Lass

Dr. Jonathan Lass

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
NANatalie A. Afshari
Natalie A. Afshari
RIRobert P. Igo
Robert P. Igo
NMNathan J. Morris
Nathan J. Morris
DSDwight Stambolian
Dwight Stambolian
SSShiwani Sharma
Shiwani Sharma
SISudha K. Iyengar
Sudha K. Iyengar
The structure of the cornea is vital to its transparency, and dystrophies that disrupt corneal organization are highly heritable. To understand the genetic aetiology of Fuchs endothelial corneal dystrophy (FECD), the most prevalent corneal disorder requiring transplantation, we conducted a genome-wide association study (GWAS) on 1,404 FECD cases and 2,564 controls of European ancestry, followed by replication and meta-analysis, for a total of 2,075 cases and 3,342 controls. We identify three novel loci meeting genome-wide significance (P<5 × 10−8): KANK4 rs79742895, LAMC1 rs3768617 and LINC00970/ATP1B1 rs1200114. We also observe an overwhelming effect of the established TCF4 locus. Interestingly, we detect differential sex-specific association at LAMC1, with greater risk in women, and TCF4, with greater risk in men. Combining GWAS results with biological evidence we expand the knowledge of common FECD loci from one to four, and provide a deeper understanding of the underlying pathogenic basis of FECD.

15 September 2017 in Annual Review of Vision Science
Verified
Journal Article
Closed access
MPMarianne Price
Marianne Price
PGPankaj Gupta
Pankaj Gupta
JLJonathan Lass
Jonathan Lass
FPFrancis W. Price
Francis W. Price
Endothelial keratoplasty (EK) has revolutionized treatment of corneal endothelial dysfunction. Compared with penetrating keratoplasty (PK), EK provides faster and more reliable visual rehabilitation while maintaining the eye's structural integrity. The number of EK procedures is growing annually and surpassed PK in the United States in 2012. The most widely used iteration, Descemet stripping endothelial keratoplasty (DSEK), implants healthy donor endothelium, Descemet membrane, and posterior stroma. Descemet membrane endothelial keratoplasty (DMEK) eliminates the donor stromal layer. Although more surgically challenging than DSEK, DMEK provides even faster visual rehabilitation and reduced risk of immunologic rejection, so its use is growing. Potential future alternatives to EK that could help address the unmet demand for donor corneas include removing central guttae and regenerating a central endothelial cell layer from healthy peripheral cells in patients with Fuchs’ dystrophy or injecting cultured human corneal endothelial cells to rehabilitate eyes without residual healthy endothelium.

1 April 2012 in Archives of Ophthalmology (1950)
Verified
Journal Article
Closed access
PDF file
LKLaura J. Kopplin
Laura J. Kopplin
KPKatie Przepyszny
Katie Przepyszny
BSBrian Schmotzer
Brian Schmotzer
KRKaren Rudo
Karen Rudo
DBDenise C. Babineau
Denise C. Babineau
FGfor the Fuchs' Endothelial Corneal Dystrophy Genetics Multi-Center Study Group
for the Fuchs' Endothelial Corneal Dystrophy Genetics Multi-Center Study Group
Research from JAMA Ophthalmology — Relationship of Fuchs Endothelial Corneal Dystrophy Severity to Central Corneal Thickness

1 November 2018 in Ophthalmology
Verified
Journal Article
Closed access
MTMark A. Terry
Mark A. Terry
AAAnthony J. Aldave
Anthony J. Aldave
LSLoretta B. Szczotka-Flynn
Loretta B. Szczotka-Flynn
WLWendi Liang
Wendi Liang
AAAllison R. Ayala
Allison R. Ayala
JLJonathan Lass
Jonathan Lass

1 December 2017 in JAMA Ophthalmology
Verified
Journal Article
Open access
PDF file
GRGeorge O. Rosenwasser
George O. Rosenwasser
LSLoretta B. Szczotka-Flynn
Loretta B. Szczotka-Flynn
AAAllison R. Ayala
Allison R. Ayala
WLWendi Liang
Wendi Liang
AAAnthony J. Aldave
Anthony J. Aldave
FGfor the Cornea Preservation Time Study Group
for the Cornea Preservation Time Study Group
In the United States and many other countries, hypothermic (2°C-8°C) corneal donor storage1 is preferred because it is less expensive than organ culture.2,3 In the United States, the most commonly used storage solution is Optisol-GS (Bausch and Lomb)4,5 and, less commonly, Life 4°C (Numedis)6,7 and Eusol (Alchimia).8,9 These solutions contain chondroitin sulfate, nonessential amino acids, antioxidants, and other components, varying between the storage solutions, that support endothelial viability until keratoplasty.9,10 Although these solutions are approved as devices by the US Food and Drug Administration for the storage of donor corneas up to 14 days prior to keratoplasty, storage time (called preservation time [PT] prior to the adoption of the ISBT [International Society of Blood Transfusion] 128 in 201511) for most cases has been less than 8 days. A survey of 19 eye banks in 2010-2011 revealed that 96% of donor corneas used for keratoplasty in the United States were stored less than 8 days, while 27% of donor corneas exported outside of North America were stored for 8 days or more.12 This practice in the United States is a result of many surgeons’ refusal to accept donor corneas with a PT longer than 7 days, although there is no scientific evidence to support this practice. Although available clinical13,14 and nonclinical evidence7,15,16 supports storage up to 14 days, consistent with US Food and Drug Administration–approved labeling, this limited evidence and continued practice pattern of the use of donor tissue stored less than 8 days for keratoplasty provide strong support for a prospective randomized clinical trial.

1 December 2017 in JAMA Ophthalmology
Verified
Journal Article
Open access
PDF file
JLJonathan Lass
Jonathan Lass
BBBeth Ann Benetz
Beth Ann Benetz
DVDavid D. Verdier
David D. Verdier
LSLoretta B. Szczotka-Flynn
Loretta B. Szczotka-Flynn
AAAllison R. Ayala
Allison R. Ayala
FGfor the Cornea Preservation Time Study Group
for the Cornea Preservation Time Study Group
Quiz Ref ID The corneal endothelium is critical for deturgescence of the corneal stroma with its barrier and pump functions.1,2 Although central endothelial cell density (ECD) decreases with age,3 it decreases at a higher rate with corneal conditions, such as Fuchs endothelial corneal dystrophy,4 and following cataract surgery.5-7 Failure of the corneal endothelium to recover from endothelial cell damage is due to its limited ability to divide.8 If central ECD falls below a critical level with an insufficient number of endothelial cells and their associated sodium-potassium adenosine triphosphatase pump sites to dehydrate the stroma,2 the cornea swells, vision decreases, and keratoplasty is then indicated. The Cornea Donor Study and its ancillary study, the Specular Microscopy Ancillary Study, which evaluated the effect of donor age on graft success and endothelial cell loss (ECL) following penetrating keratoplasty (PKP),9,10 demonstrated the importance of ECL in estimating long-term graft survival. Five years after PKP, graft success rates were similar with older and younger donor age,9 but ECL was greater with corneas from older donors compared with younger donors.11 This ECL difference at 5 years presaged a higher graft failure rate in the older donor age group by 10 years.10 In addition, ECD at 6 months, 1 year, and 5 years was associated at each time point with subsequent graft failure, irrespective of donor age.12